Determination of a clinically effective evobrutinib dose: Exposure–response analyses of a phase II relapsing multiple sclerosis study

The pharmacometric analysis of the double‐blind, randomized, phase II study (NCT02975349) investigating the safety and efficacy of evobrutinib, explored exposure–response relationships and suitable dosing regimens of evobrutinib for relapsing multiple sclerosis. Population pharmacokinetic (PK)/pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Papasouliotis, Orestis, Mitchell, David, Girard, Pascal, Dangond, Fernando, Dyroff, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747124/
https://www.ncbi.nlm.nih.gov/pubmed/36126241
http://dx.doi.org/10.1111/cts.13407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747124/
https://www.ncbi.nlm.nih.gov/pubmed/36126241
http://dx.doi.org/10.1111/cts.13407

Ejemplares similares